Immunosuppressed patients with high-risk non-muscle-invasive bladder cancer (NIMBC) can be treated successfully and safely with intravesical bacilli Calmette-Guérin (BCG), new findings suggest.

Among patients with NMIBC, BCG treatment may be less effective for patients with a history of UTUC, suggesting they are at greater risk for progression. The efficacy of intravesical Bacillus ...

A research team is shedding new light on Bacillus Calmette-Guerin (BCG), a decades-old bladder cancer treatment, which is also given as vaccine against tuberculosis. The findings could help improve ...

The BCG vaccine was introduced in 1921 and remains the only licensed vaccine for the prevention of TB worldwide. Despite its extensive use, the BCG vaccine lacks the ability to fully control the ...

In 2022, over 600,000 people across the world were diagnosed with bladder cancer, a 7.1% increase from 2020, putting their life plans on hold to receive standard of care treatments that are not always ...

The Bacillus Calmette-Guerin (BCG) vaccine can reduce the transmission of bovine tuberculosis (bTB), and routine vaccination of cattle could be used to substantially eliminate the disease within the ...

It is important to note that several reviews carried out in England, Austria, the Czech Republic, and Japan are relatively old and the findings were useful for health decision makers of respective ...